Atsushi Katsube
Minato, 1050003, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Aplastic anemia developed after treatment with durvalumab
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
Published: August 30, 2026
Geriatric nutritional risk index for the prediction of venous thrombotic events in multiple myeloma.
Geriatric nutritional risk index for the prediction of venous thrombotic events in multiple myeloma.
Journal: International journal of clinical oncology
Published: April 11, 2026
Effects of Janus kinase inhibition and interleukin 6 inhibition on serum cytokine/chemokine in idiopathic multicentric Castleman disease.
Journal: Drug discoveries & therapeutics
Published: April 01, 2026
Long-term safety and efficacy of filgotinib in patients with idiopathic multicentric Castleman disease: 52-week results from a Phase Ib clinical trial.
Journal: Modern rheumatology
Published: December 16, 2025
Geriatric nutritional risk index predicts 10-year survival in patients with multiple myeloma.
Journal: Japanese journal of clinical oncology
Published: December 16, 2025
Bronchiolitis obliterans complicating follicular lymphoma: a case series and clinical insights.
Journal: International journal of hematology
Published: August 22, 2025
Life-Threatening Pharyngolaryngeal Hematoma in a Patient With Hemophilia A.
Journal: Cureus
Published: April 26, 2025
The Impact of Tirabrutinib Monotherapy for the Treatment of Bing-Neel Syndrome: A Multicenter Retrospective Study.
Journal: American journal of hematology
Published: March 10, 2025
Dynamics of Serum Cytokines and Chemokines in Patients With Idiopathic Multicentric Castleman Disease: From a Phase Ib Investigator-Initiated Trial of Filgotinib.
Journal: Cureus
Published: February 13, 2025
Exploring the Clinical Diversity of Castleman Disease and TAFRO Syndrome: A Japanese Multicenter Study on Lymph Node Distribution Patterns.
Journal: American journal of hematology
Published: October 02, 2024
Second-line anti-CD38 monoclonal antibody therapy mitigates the negative impact of functional high-risk status in myeloma patients.
Journal: International journal of hematology
Published: September 06, 2024
Last Updated: 09/26/2026